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Objective: We have developed a technique for biologic coronary artery bypass
grafting, which is a revival of a classic concept with modern biotechnology.
Methods: Acute myocardial infarction was created by ligating the major branch of
the circumflex artery in rabbits. Animals were divided into four groups: a nontreated
group (group N), a group in which omentum was used to wrap the infarcted area
(group G), a group in which a gelatin hydrogel sheet incorporating 100 g basic
fibroblast growth factor was placed over the infarcted area (group F), and a group
in which the infarcted area was similarly treated with basic fibroblast growth factor
followed by omental wrapping (group FG). Cardiac function was subsequently
assessed by echocardiography. Postmortem angiography through the gastroepiploic
artery was done in groups G and FG. Infarct size and arteriolar density were evaluated.
Results: Group FG showed a better fractional area change than did the other groups
(group N P  .001, group G P  .002, group F P  .001). Angiography revealed
that communication from the gastroepiploic artery to the coronary artery was
created through a rich bed of neovascularization in all 7 animals of group FG,
whereas poor collaterals were recognized in only 2 of 7 animals in group G. Infarct
size was reduced to a greater extent in group FG than in groups F, G, and N (10%
 3%, 16%  5%, 19%  7%, 23%  2%, respectively, group F P  .04, groups
G and N P .01). The number of arterioles 20 to 100 m in diameter was increased
to a greater extent in group FG than in groups F, G, and N (23  5 arterioles/mm2,
14  3 arterioles/mm2, 10  1 arterioles/mm2, 4  2 arterioles/mm2, respectively),
with the differences being significant.
Conclusions: These results show that bypass from the gastroepiploic artery to
coronary arteries can be achieved without surgical anastomosis through slow release
of basic fibroblast growth factor in this rabbit acute myocardial infarction model.
This new revascularization concept, biologic coronary artery bypass grafting, could
be applicable for revascularizing many tiny coronary vessels in patients who are
difficult to treat with conventional surgery or catheter intervention.
So-called therapeutic angiogenesis was developed as an alternative toconventional treatments, such as percutaneous coronary interventionand coronary artery bypass grafting (CABG)1 for advanced coronaryartery disease. Many experimental studies have demonstrated excel-lent results.2-7 Several clinical studies with therapeutic angiogenesisin patients undergoing CABG have shown improvement in myocar-
dial perfusion according to late nuclear perfusion scans.8,9
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If the donor coronary artery from which new vessels
sprouted by angiogenetic therapy was too far from the
ischemic area, however, or if it was too small, diseased, or
stenosed, then blood flow through the neovasculature might
not be enough to supply the ischemic territory. The efficacy
of current forms of therapeutic angiogenesis may not be
sufficient for such types of coronary artery territory.
In 1936, O’Shaughnessy10 introduced a technique,
omentopexy, in which the greater omentum was brought
through the left diaphragm and wrapped around the isch-
emic heart. In 1950, Vineberg and Miller introduced inter-
nal thoracic artery implantation11 by modifying the omen-
topexy technique into a free omental graft operation.12
Although these classic procedures for treatment of angina
pectoris required a long time for graft-coronary communi-
cation to mature sufficiently, some experimental studies
have demonstrated the connection between omental vessels
and the coronary artery by angiography, and some clinical
reports have described a good outcome after pedicled or free
omental grafting.3-16
We previously reported that use of a gelatin sheet incor-
porating basic fibroblast growth factor (bFGF) can offset
sternal ischemia and accelerate sternal healing after harvest-
ing of bilateral internal thoracic arteries in not only healthy
but also diabetic rats.17,18 We also reported that prevascu-
larization with gelatin microspheres containing this angio-
genic factor can enhance the benefits of cardiomyocyte
transplantation.19 On the basis of these observations, we
considered a new strategy for revascularization of severely
diseased and tiny coronary arteries: (1) use of a healthy
large-bored donor artery, such as the gastroepiploic artery
(GEA), located near the ischemic area and (2) stimulation of
angiogenesis from this donor artery soon after administra-
tion of an angiogenic factor. In other words, the strategy is
a revival of the classic method, except that modern biotech-
nology is used (biologic coronary artery bypass grafting, or
Bio-CABG). The purpose of this study was to demonstrate
the feasibility of creating vascular communication between
tiny coronary arteries and an extracardiac artery without
surgical anastomosis by suitable placement of the artery and
use of an angiogenic factor.
Material and Methods
Preparation of Gelatin Hydrogel Sheet Incorporating
bFGF
Gelatin with an isoelectric point of 4.9 was isolated from bovine
bone collagen by an alkaline process with calcium hydroxide
(Nitta Gelatin Co, Osaka, Japan). The weight-average molecular
weight of the gelatin was 99,000 d when measured by gel filtration
chromatography relative to a standard polyethylene glycol sample.
Human recombinant bFGF with an isoelectric point of 9.6 was
obtained from Kaken Pharmaceutical Co (Tokyo, Japan). Gelatin
hydrogel sheets were prepared as described previously else-
where.17,20 The sheets were freeze-dried and then impregnated
with an aqueous solution containing 100 g bFGF to obtain gelatin
hydrogels with incorporated bFGF. The prepared hydrogel sheets
were 5  5 mm square and 0.7 mm thick. All experimental
processes were conducted under sterile conditions.
Surgical Procedure
Thirty-five Japanese white rabbits weighing 3.5 to 4.2 kg were
used. All animal procedures were conducted in accordance with
the “Guide for the Care and Use of Laboratory Animals” (http://
www.nap.edu/catalog/5140.html). All studies were approved by
the Animal Research Committee of Kyoto University School of
Medicine.
After intravenous injection of sodium pentobarbital (30 mg/kg),
oral intubation was performed, and the animals received mechan-
ical ventilation (model 683; Harvard Apparatus, South Natick,
Mass) at a tidal volume of 15 mL and a minute ventilation rate of
80. General anesthesia was maintained with 1.5% to 2.0% isoflu-
rane mixed with oxygen. The heart and omentum were exposed
through a median sternotomy and laparotomy. The major branch of
the circumflex artery was permanently ligated with 4-0 polypro-
pylene suture to create acute myocardial infarction (MI). Lidocaine
(1 mg/kg) was administered intravenously before the completion
of this procedure. Careful inspection was maintained for 10 min-
utes after the ligation. Ischemia was confirmed by blanching down-
stream of the ligation and by persistent ST elevation on the
electrocardiogram. The omentum was taken out from the perito-
neal space into the mediastinum, preserving the arch structure of
the GEA. The animals were divided into four groups that received
different types of adjunct therapy as follows: group N (n  7,
control) received no additional treatment after creation of the MI;
in group G (n  8) the omentum including the GEA was wrapped
around the infarcted area; in group F (n  10) a gelatin hydrogel
sheet incorporating 100 g bFGF was placed over the epicardium
of the infarcted area; and in group FG (n  10) a gelatin hydrogel
sheet incorporating 100 g bFGF was placed over the epicardium
of the infarcted area, followed by omental wrapping (combined
therapy). The bFGF-impregnated hydrogel sheets were fixed to the
surface of the heart by stitching with 5-0 polypropylene suture.
Before the incision was closed with discontinuous tissue layers,
residual air was evacuated from the thorax through silicone tubing
attached to a 10-mL syringe. All rabbits were awake within 1 hour
after the operation and were kept in an air-conditioned room that
was cleaned daily. The rabbits were given free access to water and
food thereafter. All animal handling and experiments were con-
ducted in a gentle manner to minimize stress and discomfort to the
rabbits, in compliance with the “Guidelines for Use of Laboratory
Animals at Kyoto University.”
Echocardiographic Measurements
A commercially available echocardiograph (model SSH-260A Ul-
trasound System; Toshiba Medical, Inc, Tokyo, Japan) including a
7.5-MHz pediatric transducer was used for all studies. Echocar-
diographic studies were performed before the operation and at 2
and 4 weeks of follow-up. All studies were done with the animals
under light anesthesia with intravenous sodium pentobarbital in-
jection under spontaneous respiration. Global ventricular function
was estimated by calculating the fractional area change (FAC) of
the left ventricle (LV). Two-dimensional M-mode midventricular
Ueyama et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 6 1609
A
CD
short-axis images were obtained through a right parasternal ap-
proach to determine the FAC by tracing frame by frame through-
out the entire cardiac cycle. For each measurement, three consec-
utive cardiac cycles were averaged. All analyses were done by
another observer (K.D.), who was blinded to treatment groups.
Postmortem Angiography
Communication between the coronary arteries and branches of the
GEA in the omentum was evaluated by postmortem angiography
at 4 weeks after the operation in groups G and FG. After intuba-
tion, relaparotomy was performed, taking care to avoid injuring the
omentum. A 24-mm venous catheter was inserted through the
celiac artery, which forms the root of the GEA, and fixed. The
chest was reopened to expose the heart wrapped with the omen-
tum. The rabbits were killed with an overdose of pentobarbital, and
then the heart and omentum were removed en bloc. A 20-mL
portion of heparinized physiologic sodium solution was flushed
through the venous catheter into the GEA.
Angiography was performed with an x-ray angiography system
(DFW-10B; Toshiba Medical). Angiograms were taken four times
every 3 seconds after the start of manual injection of nonionic
contrast medium for later analysis (Figure 1). A 3-mL portion of
contrast medium was injected by hand for 5 seconds in all cases.
Quantitative angiographic analysis of collateral vessel develop-
ment was performed with a grid overlay composed of 2.5-mm
diameter circles arranged at random in the LV distant from the
GEA itself. The total number of grid intersections in the LV area,
as well as the total number of intersections crossed by a contrast-
opacified artery, were counted in a single-blind manner. An an-
giographic score was calculated for each film as the ratio of grid
intersections crossed by opacified arteries divided by the total
number of grid intersections in the LV area.
Histologic Analysis of MI Area and Arteriolar Density
After the angiography, the heart was cut into 2-mm thick slices
from apex to base in groups G and FG. In groups N and F, the
same procedure was performed after the animals had been killed.
The slices were immersed in buffered triphenyltetrazolium chlo-
ride (TTC) solution and then photographed, and infarct size was
calculated with image analysis software (NIH Image 1.61; Na-
tional Institutes of Health, Bethesda, Md). Each image was ana-
lyzed five times and averaged. Infarct size was defined as the
percentage of the infarction area within the total area of the LV in
each histologic section. As dimensional analysis of the infarction
area, three equally spaced measurements of infarct wall from same
slices were performed to determine average wall thickness. At the
same time, endocardial circumferential length of LV and the scar
were measured. For both infarct size and dimensional measure-
ments, the observer was blinded to treatment group. The midcavity
area, not used for TTC immersion, was fixed in 4% paraformal-
dehyde, embedded in paraffin, and cut into sections 5 m thick.
The sections were stained with Masson trichrome to evaluate
collagen deposition in comparison with TTC staining.
Other midcavity sections fixed in 4% paraformaldehyde were
stained with a monoclonal antibody against –smooth muscle
actin (Sigma, St Louis, Mo), followed by incubation with anti-
mouse immunoglobulin G (whole molecule). Tetramethylrhodam-
ine isothiocyanate–conjugated secondary antibody (Sigma) was
used to detect –smooth muscle cells of arterioles. The sections
were counterstained with hematoxylin, eosin, or both. The num-
bers of arterioles were counted at the infarction border zone under
fluorescence microscopy (100) to determine the arteriolar den-
sity. Five fields from one section were randomly selected for the
arteriole counts. An arteriole was defined as a vessel with a
diameter of 20 to 100 m. Quantification was performed in a
Figure 1. Schema of postmortem angiography. Contrast medium is injected into GEA through small cannula
manually inserted through celiac artery. X-ray photograph is taken as in illustration (right).
Surgery for Acquired Cardiovascular Disease Ueyama et al
1610 The Journal of Thoracic and Cardiovascular Surgery ● June 2004
A
CD
blinded manner with a minimum of three sections for each animal.
All animals were used for the analysis.
Statistical Analysis
Results are expressed as mean  SD. Comparisons of echocardi-
ography data among the groups were performed by 2-way analysis
of variance (ANOVA). Comparisons of other data among the
groups were conducted by 1-way factorial ANOVA. If significance
was found for a group, a time effect, or a group-by-time interac-
tion, differences between groups at the same point in time were
assessed with 1-way ANOVA followed by post hoc comparisons,
when appropriate, with the Student-Newman-Keuls method. Sta-
tistical analyses were performed with Statview for Windows ver-
sion 5.0 (SAS Institute Inc, Cary, NC).
Results
Global Cardiac Function Assessed by
Echocardiography
Figure 2 shows the changes in FAC and LV end-diastolic
area (LVEDA). None of the FAC and LVEDA values in any
of the groups were different before the operation. Two-way
ANOVA for FAC showed strong group and time effects and
a high group-by-time interaction (respectively F 9.4, P
.0001, F  20.0, P  .0001, and F 4.1, P .0014).
At 2 weeks after the procedure, FAC values in group FG
were significantly higher than in groups N, G, and F (P 
.03, P  .04, and P  .02, respectively). At 4 weeks, group
FG showed higher FAC values than did the other three
groups (group FG 65  7, group N 46  1, P  .0004,
group G 51 7; P .002, and group F 46 4, P .0005).
The changes in LVEDA values, which indicate the load-
ing conditions of LV, showed a pattern similar to that of
FAC. At 4 weeks, LVEDA was significantly lower in group
FG than in groups N and G. No difference reached signif-
icance, but LVEDA in group FG had a tendency to be low
compared with group F (group FG 198  45 mm2, group N
280  50 mm2; P  .001, group G 275  35 mm2, P 
.003, and group F 250  52 mm2, P  .06).
Communication Between Coronary Arteries and the
GEA in Terms of Angiographic Assessment and
Angiographic Score
Angiography was performed in 7 animals in each of groups
FG and G. Communication from the GEA was created to the
coronary artery though rich collaterals in all 7 animals of
group FG. On the other hand, the circumflex artery was
identified through poor collaterals in 2 of 7 animals of group
G. Representative angiograms recorded from groups FG
and G are shown in Figure 3, A. The angiographic score in
group FG (0.82 0.13) was significantly (P .001) higher
than that in group G (0.1  0.11; Figure 3, B).
Infarct Size and Dimensional Analysis of MI
MI was recognized at the anterolateral wall of the LV,
posterolateral wall of the LV, or both in all groups, although
there was difference in the infarct size. The infarct ratios
determined by analysis of TTC staining in groups N, G, and
F were 23%  2%, 19  7%, and 16%  5%, respectively,
which were significantly higher than that in group FG (10%
 3%) (P  .001, P  .001, and P  .04 for each of the
groups; Figure 4). There was no difference between groups
G and F. MI size was reduced to a greater extent in group
F than in group N (P  .03). Although there was no
significant difference in average wall thickness in all
Figure 2. FAC (A) and LVEDA (B) assessed by echocardiography before operation and at 2 and 4 weeks’ follow-up.
Pre Tx, Before treatment. Asterisk indicates P < .05 versus groups N, G, and F; dagger indicates P < .001 versus
groups N, G, and F; two daggers indicate P < .01 versus groups N, G, and F.
Ueyama et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 6 1611
A
CD
groups, circumferential lengths of LV and the scar were
lower in group FG than the other three groups (Table 1).
Immunohistochemical Analysis of New Vessel
Formation
Immunohistochemical staining for anti––smooth muscle
actin revealed that the number of arterioles was increased in
the following order: group FG (23  5) more than group F
(14  3) more than group G (10 1) more than group N (4
 2), with each of the differences being significant (Figure
5, A). Figure 5, B, shows representative photomicrographs
(original magnification 100) for groups G and FG.
Discussion
Multiple experimental and clinical studies have obtained
promising results with therapeutic angiogenesis as an alter-
native to conventional percutaneous coronary intervention
or CABG for coronary artery disease that otherwise would
have no treatment options.2-9 If, however, the donor coro-
nary artery was too far from the target area, too tiny, or
diseased or stenosed, conventional therapeutic angiogenesis
might not be sufficiently efficacious. Therefore we have
proposed a revival of the classic revascularization technique
of omentopexy by adding a modern biotechnologic tool,
slow release of an angiogenic factor, as an optional strategy
for therapeutic angiogenesis.
In this study, the combined therapy involving omento-
pexy and bFGF administration (group FG) preserved car-
diac function better than was seen in the other groups, not
only by reducing MI size but also by increasing the number
of arterioles. Although myocardial blood flow and hemody-
namics were not measured, objective data including post-
mortem angiography suggested that numerous functional
neovessels were connected to the coronary artery from the
donor artery. However, the true mechanism of this efficacy
was not clear. The pathogenesis of MI, which can be acutely
completed within 24 hours, could not be altered by angio-
Figure 3. A, Representative postmortem angiogram in groups
with omental wrapping (group G) and omental wrapping with
bFGF (group FG). Left, in group G, GEA in omentum is opacified,
but no communication to coronary arteries is identified. Right, in
group FG, numerous collaterals are created between GEA and
occluded coronary arteries. B, Angiographic score calculated by
postmortem angiographic analysis in groups with omental wrap-
ping (group G) and omental wrapping with bFGF (group FG).
Asterisk indicates P < .001 versus group FG.
Figure 4. Infarction ratios (% of whole LV) determined by analysis
of TTC staining. Asterisk indicates P < .01 versus group FG;
dagger indicates P < .05 versus group F; two daggers indicate
P< .05 versus group FG.
TABLE 1. Dimensional analysis of the scar
LV circumferential
length (mm)
Circumferential length
of scar (mm)
Infarct wall
thickness (mm)
Group N 61 8 27 4 1.9 0.4
Group G 58 5 28 5 2.1 0.7
Group F 56 8* 24 4 2.0 0.2
Group FG 48 3† 16 2‡ 2.5 0.4
*P  .005 versus group FG.
†P  .001 versus groups N and F.
‡P  .001 versus groups N, G, and F.
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genesis. It is possible that the Bio-CABG altered the remod-
eling process of scar tissue clearance in this study. Preser-
vation of better cardiac function and reduction in MI size
may be related to differences in the size of the ventricle
caused by altering the remodeling process. The results of
dimensional analysis of scar and difference of loading con-
dition were consistent with this presumption.
Omentum including the GEA has classically been used
for surgical treatment of not only ischemic heart disease but
also complex cardiothoracic problems21,22 because the
omentum possesses a rich blood and lymph supply and has
the additional benefit of producing an angiogenic factor,
vascular endothelial growth factor.23 In addition to this
unique functional character, an omental flap has the advan-
tage of being able to reach and wrap a target organ entirely
because of its intrinsic structure. The GEA has become
firmly established as an in situ graft conduit with low
morbidity, including abdominal complications.24 The weak
point of omentopexy for myocardial revascularization is its
slow and insufficient angiogenesis, similar to that of the
Vineberg operation. In this study, we added a bFGF-con-
taining gelatin sheet to the omental wrapping, and this was
found to accelerate angiogenesis effectively relative to
omentopexy alone.
Previous studies have shown that gene encoding, virus
mediation, and direct injection into the coronary artery or
intrapericardially are useful mechanisms for delivering an
angiogenic factor to its target.2-7 The method used for
delivering angiogenic protein in this study was technically
simpler and more reliable, and, because it did not involve
genes or viruses, it would also be less likely to have adverse
effects on a patient. We have reported that prevasculariza-
tion with bFGF-containing microspheres enhanced the ben-
efits of cardiomyocyte transplantation without increasing
the serum level of bFGF (no systemic effects).19 Although
the technique of delivering bFGF in this study, gelatin
sheets attached to the epicardium, differed from injection of
beads into the myocardium, the sheets were made of the
same material as the beads, and the rate of bFGF release was
almost the same. We therefore consider this delivery
A
B
Figure 5. A, Number of arterioles counted by immunohistochemical staining. Arteriole was defined as vessel with
diameter of 20 to 100 m. Asterisk indicates P < .001 versus group FG; two daggers indicate P < .01 versus group
G; dagger indicates P < .05 versus group F. B, Representative immunohistochemical staining photos (original
magnification 100) in groups with omental wrapping (group G) and omental wrapping with bFGF (group FG).
Arterioles in border zone of MI are stained by anti––smooth muscle actin. White arrows indicate arterioles. Blue
bar at lower right is scale of 100 m.
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method with gelatin hydrogel to be potentially excellent and
widely applicable to other growth factors.
In a clinical setting, Bio-CABG will probably be appli-
cable for treatment of diffuse coronary artery disease that
cannot be treated by percutaneous coronary intervention or
conventional CABG. This type of coronary artery disease is
often recognized in patients receiving hemodialysis or those
with severe diabetes mellitus. Even in the era of drug-
eluting stents, tiny coronary arteries remain a difficult target
for interventional catheters. Therefore Bio-CABG has the
potential to be a promising new avenue for so-called no
option patients with severe coronary disease.
This study was limited as a means of assessing therapeu-
tic angiogenesis in the sense that the acute MI model differs
from the clinical situation. Furthermore, myocardial blood
flow and hemodynamic effects were not assessed. Angiog-
raphy and histologic examination do not establish evidence
of increased perfusion. Therefore in a future study we are
planning to try to estimate myocardial blood flow and the
practical efficacy of Bio-CABG directly with the chronic
ischemia model in a large animal. Another limitation is that
the method for delivering bFGF in this study may not be as
good as our previous technique of implanting biodegradable
capsules or other techniques,8,9 because the attachment of
the gelatin sheet to the epicardium may not provide suffi-
cient angiogenic stimuli to the mid or endocardial region of
the LV. The omental wrapping may not provide long-term
perfusion of the myocardium, and short-term benefits would
be anticipated with this procedure. A small MI area was
produced in this study even in the control animals. This
finding may be related to the use of TTC staining for a short
time, which may reduce the accuracy of infarct identifica-
tion.
In conclusion, we have demonstrated that Bio-CABG
can be used to create marked communication between tiny
coronary arteries and an extracardiac artery by administra-
tion of slow-release bFGF, without surgical anastomosis.
This new concept, in which modern biotechnology has been
used to revive a classic operation, has the potential to offer
revascularization for patients with coronary artery disease
who have no other treatment options.
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Discussion
Dr Hiroyuki Tsukui (Pittsburgh, Pa). I have two questions.
First, how long does the bFGF effect last? Second, what is an
appropriate volume? Do you use 100 g?
Dr Ueyama. We use the administration method of bFGF by
gelatin hydrogel sheet. We used that dose of, as you say, 100 g
bFGF only in this study. But in another study we have already
reported that a 100-g dose of bFGF was enough to inducing
angiogenesis for another target organ.
Dr Tsukui. So do you mean that a flow rate of 100 g is
appropriate? Or if you used it 12 or more weeks at 200 g or
another dose, would that be better for revascularization?
Dr Ueyama. I don’t have an exact answer to your question
now, but I’d guess that one would not need to use more than 100
for FGF for better effect.
Dr Andrew S. Wechsler (Philadelphia, Pa). Did you happen
to look and see how deep in the myocardium the new blood vessels
went? Did they reach the subendocardial surface or the mid myo-
cardium, or was it primarily an epicardial blush?
Dr Ueyama. I think the results of angiography suggested that
the new vessel from the GEA passed through the epicardium and
myocardium and bypassed to the coronary artery.
Dr Virna Sales (Boston, Mass). Would you be able to see a
prospective microencapsulating this bFGF with a hydrogel and
have that kind of delivery?
Dr Ueyama. Yes, we did. The material is the same that we used
in this study.
Dr Sales. But would that be possible to microencapsulate this?
Dr Ueyama. In another study we used microspheres including
bFGF injected into myocardium. Many angiogenesis occurred in
the myocardium between each coronary artery but not from an
extracardiac donor artery.
Dr Sales. What is the degradation time of this hydrogel? You
said it was biodegradable.
Dr Ueyama. It takes about 7 to 10 days for complete degra-
dation.
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